Bio-Techne
TECH
$56.26
+1.17%
Bio-Techne Corp. is a life sciences manufacturer that supplies essential consumables and instruments to the pharmaceutical, biotechnology, academic, and diagnostic research markets. The company is a well-established player in the biotechnology sector, operating through two primary segments: Protein Sciences, which generates about 75% of revenue from reagents and analytical instruments, and Diagnostics and Genomics, which contributes the remaining 25%. The current investor narrative is dominated by a challenging operational environment, as evidenced by recent quarterly results showing flat revenue growth and a significant year-over-year decline in net income, raising questions about near-term demand and margin pressures in its core research markets. Attention is focused on the company's ability to navigate a difficult funding landscape for biotech research and demonstrate a return to profitable growth.…
TECH
Bio-Techne
$56.26
Investment Opinion: Should I buy TECH Today?
Rating: Hold. The core thesis is that TECH is a high-quality company in a cyclical downturn, but its premium valuation fully prices in a recovery, leaving limited margin for error and skewed risk/reward.
Supporting evidence includes a forward P/E of 28.2x based on analyst EPS estimates of $2.66, which is rich for the current growth profile. While free cash flow generation is strong at $223 million TTM and the balance sheet is solid (D/E 0.23), these strengths are offset by flat YoY revenue growth of -0.39% and a declining net margin of 6.02%. The stock's 27.42% one-month surge suggests the near-term rebound may already be pricing in improved sentiment, leaving it vulnerable to a pullback.
The two biggest risks are 1) a failure of revenue to re-accelerate, leading to multiple compression from its lofty P/S of 6.64x, and 2) continued margin pressure invalidating the analyst EPS recovery thesis. This Hold would upgrade to a Buy if the forward P/E compressed below 20x on sustained earnings power, or if quarterly revenue growth consistently returned to >5% YoY. It would downgrade to a Sell if revenue growth turns negative or if the stock fails to hold support above $50, signaling a breakdown of the recent recovery. The stock is currently overvalued relative to its near-term fundamentals but fairly valued for a patient investor betting on a 2026-2027 operational turnaround.
Sign up to view all
TECH 12-Month Price Forecast
The investment case for TECH hinges entirely on the execution of a promised earnings recovery, which is already reflected in its forward P/E of 28.2x. While the company's strong cash flow and balance sheet provide a floor, the premium sales multiple leaves no room for error. The recent 27% bounce from lows suggests the easy money from oversold conditions has been made. The stance is neutral, as the risk of valuation compression in a no-growth scenario is balanced by the potential for a cyclical upturn in its end markets. Confidence is medium due to the high uncertainty around the timing of a biotech funding recovery. The stance would turn bullish on evidence of sustained revenue acceleration (>5% YoY) and margin expansion; it would turn bearish if the stock breaks below $50, signaling a failure of the recent recovery attempt.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bio-Techne's 12-month outlook, with a consensus price target around $73.14 and implied upside of +30.0% versus the current price.
Average Target
$73.14
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$45 - $73
Analyst target range
The stock has moderate analyst coverage with 6 firms providing estimates, and the institutional ratings show a generally bullish tilt with recent actions including 'Buy' from Citigroup and UBS and 'Overweight' from Wells Fargo, though Stifel maintains a 'Hold'. The consensus appears to lean positive, with the average revenue estimate for the next period at $1.56 billion and EPS at $2.66, implying expectations for a recovery from current depressed levels. The implied upside or downside to a consensus price target cannot be calculated as the average target price is not provided in the data.
The target price range is not explicitly provided, but the wide dispersion in estimated EPS (low of $2.57 to high of $2.95) suggests some uncertainty around the pace of the expected earnings recovery. The high-end estimates likely assume successful margin improvement and a rebound in instrument sales, while the low-end may reflect concerns about prolonged softness in biotech funding. The recent rating actions in February 2026 were largely reiterations, indicating analysts are in a 'wait-and-see' mode following the company's latest results, with the wide target spread typical for a stock in transition.
Bulls vs Bears: TECH Investment Factors
The evidence currently tilts bearish, as the company's elevated valuation multiples (P/S 6.64x, EV/Sales 7.31x) are fundamentally misaligned with its stalled revenue growth (-0.39% YoY) and declining profitability (net margin 6.02%). While strong free cash flow ($223M TTM) and analyst expectations for an earnings recovery provide a bull case, these are contingent on a future operational turnaround that has yet to materialize. The single most important tension in the investment debate is whether the company's significant premium valuation can be justified by a return to mid-to-high single-digit revenue growth and margin stabilization, or if continued stagnation will trigger a painful valuation compression towards sector averages.
Bullish
- Strong Free Cash Flow & Balance Sheet: The company generates robust free cash flow of $223 million TTM, providing significant financial flexibility. Its balance sheet is solid with a low debt-to-equity ratio of 0.23 and a high current ratio of 3.46, insulating it from funding pressures.
- Analyst Expectations for Earnings Recovery: Analysts forecast a significant earnings rebound, with forward EPS estimates averaging $2.66, implying a forward P/E of 28.2x. This represents a dramatic normalization from the depressed trailing P/E of 110.4x, suggesting the market views current weakness as temporary.
- Recent Powerful Technical Rebound: The stock has surged 27.42% over the past month from deeply oversold levels near its 52-week low of $43.20. This high-beta (1.358) bounce suggests aggressive buying interest and potential for a trend reversal if momentum is sustained.
- Recurring Consumables Revenue Base: Approximately 75% of revenue comes from the Protein Sciences segment, heavily weighted towards reagents and consumables. This provides a stable, recurring revenue stream of $235.4 million last quarter, offering a defensive foundation during the instrument sales downturn.
Bearish
- Stalled Revenue & Profitability Decline: Recent quarterly revenue of $295.9 million showed a year-over-year decline of -0.39%, indicating a challenging demand environment. Net income of $38.0 million represents a sharp drop from $49.1 million two years prior, with gross margin contracting to 64.65%.
- Extremely High Valuation Multiples: The stock trades at a significant premium with a P/S of 6.64x and EV/Sales of 7.31x, which is elevated for a company with flat growth. The negative PEG ratio of -1.97 highlights the disconnect between its high multiple and negative growth expectations.
- Severe Technical Downtrend & High Volatility: The stock remains down 39.33% from its 52-week high of $72.16, signaling significant technical damage. Its high beta of 1.358 makes it approximately 36% more volatile than the market, amplifying downside risk during sector weakness.
- Weak Return Metrics & Earnings Volatility: Return on equity has fallen to just 3.83%, reflecting poor capital efficiency amid profitability challenges. Quarterly earnings are volatile, as evidenced by a net loss of -$17.7 million in June 2025, raising concerns about earnings quality and predictability.
TECH Technical Analysis
The stock is in a pronounced downtrend, having declined approximately 39.33% from its 52-week high of $72.16 to a recent low of $43.20, placing it near the bottom of its 52-week range and signaling significant technical damage. With a 1-year price change of +15.58% but a 6-month change of -0.57%, the stock has given back nearly all its gains from the first half of the period, indicating a strong reversal from earlier strength. The recent 1-month surge of +27.42% suggests a powerful short-term rebound from oversold conditions, though this momentum is occurring from a deeply depressed base and against a backdrop of negative relative strength versus the S&P 500, which is down -9.41% over the past year.
Recent momentum shows a sharp but potentially fragile recovery, with the stock up 27.42% over the past month and 12.55% over the past three months, diverging positively from its longer-term weakness. This rally, however, follows a steep decline from the $70s in January to the mid-$40s in May, and the stock remains well below its 52-week high. The elevated beta of 1.358 indicates the stock is approximately 36% more volatile than the broader market, which has contributed to its amplified drawdown and subsequent bounce, typical of high-beta names in a recovery phase.
Key technical levels are clearly defined, with major support at the 52-week low of $43.20 and primary resistance at the 52-week high of $72.16. A sustained break above the recent recovery highs near $58 would be needed to signal a more durable trend reversal, while a failure to hold the $50 level could see a retest of the lows. The stock's high beta of 1.358 underscores its sensitivity to market sentiment and sector rotation, making risk management and position sizing critical for investors considering exposure during this volatile consolidation phase.
Beta
1.36
1.36x market volatility
Max Drawdown
-39.3%
Largest decline past year
52-Week Range
$43-$72
Price range past year
Annual Return
+14.1%
Cumulative gain past year
| Period | TECH Return | S&P 500 |
|---|---|---|
| 1m | +16.7% | -1.6% |
| 3m | +6.8% | +11.7% |
| 6m | -5.0% | +6.3% |
| 1y | +14.1% | +22.2% |
| ytd | -5.7% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TECH Fundamental Analysis
Revenue growth has stalled, with the most recent quarterly revenue of $295.9 million representing a slight year-over-year decline of -0.39%, indicating a challenging demand environment. Sequentially, revenue increased from $286.6 million in the prior quarter, but the flat YoY performance, following a significant revenue drop in the June 2025 quarter, points to ongoing top-line pressure. The revenue segment data shows the business is heavily reliant on consumables, which generated $235.4 million last quarter, while instruments contributed $29.6 million and royalties $8.5 million, suggesting stability in the recurring consumables base but weakness in higher-margin instrument sales.
Profitability has deteriorated significantly, with net income of $38.0 million in the last quarter representing a sharp decline from $49.1 million in the same quarter two years prior, and gross margin contracting to 64.65% from higher levels historically. The operating margin of 8.38% (from valuation data) and net margin of 6.02% reflect substantial compression, though the company remains profitable on a GAAP basis with positive EPS of $0.24. The quarterly trend shows volatility, with a net loss of -$17.7 million reported in June 2025 due to significant other expenses, highlighting earnings quality concerns.
The balance sheet remains solid with a strong current ratio of 3.46 and a conservative debt-to-equity ratio of 0.23, indicating low financial leverage. Free cash flow generation is healthy at $223.0 million on a trailing twelve-month basis, providing ample liquidity to fund operations and the dividend. However, return on equity has fallen to just 3.83%, reflecting the profitability challenges, while the company's ability to generate cash from operations ($82.4 million last quarter) supports its financial flexibility despite the earnings pressure.
Quarterly Revenue
$295877000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.64%
Latest Quarter
Free Cash Flow
$223020000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TECH Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E of 110.4x is exceptionally high, reflecting depressed earnings, while the forward P/E of 28.2x suggests analysts expect significant earnings recovery. The wide gap between trailing and forward multiples indicates the market is pricing in a substantial normalization of profitability, with current depressed earnings seen as temporary rather than structural.
Compared to sector averages, Bio-Techne trades at a significant premium on a sales basis, with a P/S ratio of 6.64x and EV/Sales of 7.31x, which are elevated for a company experiencing flat revenue growth. The forward P/E of 28.2x also appears rich relative to likely sector averages for life sciences tools companies, suggesting the market continues to assign a quality premium for its established market position and strong cash flow generation despite recent operational headwinds.
Historically, the stock's valuation has compressed from much higher levels, with the current P/S ratio of 6.64x sitting below its 5-year peak but above levels seen during stronger growth periods. The forward P/E of 28.2x represents a meaningful discount to historical peaks but remains elevated relative to the company's current growth profile, indicating the stock is not deeply cheap despite the significant price decline. The negative PEG ratio of -1.97 further highlights the disconnect between its high multiple and negative growth expectations embedded in analyst estimates.
PE
109.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -113x~293x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
38.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on profitability and valuation. The company faces significant margin pressure, with gross margin contracting to 64.65% and operating margin at just 8.38%. Earnings are volatile, as shown by the quarterly net loss of -$17.7 million in June 2025. The primary risk is valuation compression; with a P/S of 6.64x and flat revenue, any disappointment in the anticipated growth recovery could lead to a severe multiple derating. The company's high reliance on biotech research funding makes its revenue sensitive to capital expenditure cycles in its end markets.
Market & Competitive Risks are heightened by the stock's premium valuation and high volatility. Trading at a P/S of 6.64x, the stock is vulnerable to sector rotation away from expensive life sciences tools names, especially if interest rates remain elevated. Its high beta of 1.358 means it will experience amplified moves during broader market downturns. Competitive pressures and potential pricing erosion in its core reagent markets could further pressure already declining margins. The recent news highlighting a market focused on AI and record indices underscores a risk of capital flowing away from traditional biotech suppliers like TECH.
The Worst-Case Scenario involves a failure of the expected earnings recovery, leading to simultaneous downward revisions to growth estimates and a compression of its premium sales multiple. This could be triggered by a prolonged downturn in biotech funding, causing instrument sales to remain weak and consumables growth to stagnate. In this adverse scenario, the stock could realistically retest and break below its 52-week low of $43.20. From the recent price near $58, this represents a potential downside of approximately -25%. A re-rating towards a more typical sector P/S multiple for a no-growth company could drive losses even beyond this level.
FAQ
The key risks are, in order of severity: 1) Valuation Compression Risk: The primary danger is the stock's premium sales multiple (P/S 6.64x) contracting if growth remains stagnant, potentially leading to a 20-30% decline. 2) Operational Risk: Continued pressure on gross margins (currently 64.65%) and volatile earnings, as seen in the Q4 2025 net loss, threaten the earnings recovery thesis. 3) Market/Sector Risk: The stock's high beta of 1.358 makes it highly sensitive to broader market downturns and sector rotation away from expensive healthcare names. 4) End-Market Risk: Revenue is heavily dependent on funding for biotech and academic research, which is currently in a downturn and outside the company's control.
The 12-month forecast for TECH is a range-bound outcome with a neutral bias. The base case (60% probability) sees the stock trading between $58 and $65 as it digests its recent rebound and awaits clearer signs of a fundamental recovery. The bull case (25% probability) targets a return to the $68-$72 range on successful execution of the earnings rebound. The bear case (15% probability) warns of a retest of support between $43 and $50 if operational challenges persist. The most likely scenario is the base case, which assumes the company meets consensus EPS estimates of $2.66 but struggles to re-accelerate revenue growth meaningfully, keeping its premium valuation in check.
TECH stock is overvalued based on its current fundamentals but may be fairly valued if the anticipated recovery materializes. On a trailing basis, metrics are distorted by depressed earnings (P/E 110.4x). More importantly, its price-to-sales ratio of 6.64x and EV/Sales of 7.31x are at a significant premium to many peers, especially for a company with flat YoY revenue growth. The forward P/E of 28.2x implies the market is paying for a substantial profit rebound. The valuation implies the market expects a successful return to mid-single-digit revenue growth and margin stabilization. Until that is demonstrated, the stock carries valuation compression risk.
TECH is a speculative buy at current levels, suitable only for investors with a high risk tolerance and a long-term horizon. The bullish case rests on a significant earnings recovery (forward EPS $2.66) from depressed levels, but this is already reflected in its forward P/E of 28.2x and premium P/S of 6.64x. The 25%+ downside risk to the 52-week low of $43.20 is meaningful. It could be a good buy for investors who are confident in a near-term rebound in biotech research funding and can withstand the stock's high volatility (beta 1.358). For most, it is better to wait for concrete evidence of revenue re-acceleration before committing capital.
TECH is unsuitable for short-term trading due to its high volatility (beta 1.358) and lack of near-term positive catalysts; its recent 27% monthly surge may already be over. It is better suited for a long-term investment horizon of 2-3 years for investors betting on a cyclical recovery in its end markets. The company's strong free cash flow and low dividend yield (0.62%) indicate it is a capital appreciation story, not an income stock. The minimum suggested holding period is 12-18 months to allow for the anticipated operational turnaround to either materialize or fail, providing clarity on the investment thesis. Position sizing should be conservative due to the elevated risk profile.
